March 19, 2026

Blue Wellington Appoints Dan Kiley as Chief Investment Officer of bi-one®

Blue Wellington Appoints Dan Kiley as Chief Investment Officer of bi-one®

aesthetic medicine, announcements, bi-one, Biodermogenesi, Blue Wellington, capital management, chief investment officer, clinical aesthetics, Dan Kiley, FDA de novo application, healthcare innovation, investment leadership, medical technology, medtech leadership, non-invasive treatment, regenerative skincare

A seasoned investment executive with nearly four decades of asset management and entrepreneurial experience, Kiley brings a disciplined capital stewardship framework to one of aesthetic medicine’s most promising emerging platforms.

Atlanta, GA — [Month Day, Year]

Blue Wellington, LLC, the medical technology accelerator and parent company of bi-one®, today announced the appointment of Dan Kiley as Chief Investment Officer of bi-one®. Kiley brings to the role a 38-year track record of building, scaling, and stewarding high-value investment enterprises — most notably as Founder and Chief Executive Officer of Retirement Corporation of America (RCA), a nationally recognized investment advisory firm that he built from inception and ultimately sold to Fifth Third Bank in 2017. In May 2022, RCA was reacquired by an investor group that included Kiley, who returned to the firm as Chief Investment Officer, where he currently oversees $800 million in client assets under management.

Kiley’s appointment reflects Blue Wellington’s continued commitment to building the operational and financial infrastructure required to take bi-one® to scale in the United States market. As the company advances its FDA de novo classification application and prepares for commercial launch, disciplined capital allocation and investment oversight are mission-critical. Kiley will assume responsibility for investment management and portfolio oversight across the bi-one® platform, working in close coordination with Blue Wellington’s executive leadership and its growing network of strategic advisors.

Beyond RCA, Kiley has demonstrated a consistent pattern of identifying and building category-defining businesses. He co-founded Money Masters, one of America’s first online investment advisory services; Retirement University, a continuing education platform serving the retiree community; and Diligent Corporation, whose flagship product — Diligent Board Books — is today used by more than 25,000 companies globally for the secure digital transmission and storage of confidential corporate information. He also serves as General Partner of Scenic Land Investments, the development partnership behind McLemore, a premier golf, hotel, and residential community in Rising Fawn, Georgia, and has served as past Chairman of Arria, a global AI natural language generation technology company.

“Dan has spent nearly four decades doing exactly what bi-one® requires of its CIO: building enterprises of lasting value, deploying capital with discipline, and knowing how to bring transformative ideas from early conviction to durable commercial reality. As we approach a pivotal regulatory and commercial inflection point, having Dan in this role gives us and our investors exactly the kind of rigorous oversight and financial credibility that this opportunity demands.”

— Keith Knutsson, Founder & CEO, Blue Wellington, LLC

“I have spent my career identifying businesses with genuine differentiation and building the financial structures to take them where they deserve to go. bi-one® is exactly that kind of opportunity. The clinical evidence behind Biodermogenesi® is unlike anything I have encountered in consumer healthcare — it is rigorous, replicable, and commercially underexploited. I am proud to join Blue Wellington at this stage of bi-one’s development and look forward to helping build the investment infrastructure that reflects this platform’s true potential.”

— Dan Kiley, Chief Investment Officer, bi-one® / Blue Wellington, LLC

Blue Wellington acquired bi-one® LifeTouchTherapy platform from Expo Italia Srl, the Florence-based medical device company. Biodermogenesi®, the underlying technology behind bi-one LifeTouchTherapy, was developed through over two decades of clinical research conducted in collaboration with the Universities of Pisa, Pavia, and Verona. Biodermogenesi® is a patented, non-invasive treatment that stimulates the production of new skin tissue — generating new collagen and elastic fibers, restoring melanocyte activity, and restructuring damaged dermal architecture — with no downtime, no needles, and no reported side effects across a documented patient population exceeding 1,000. The platform holds CE-mark clearance and Blue Wellington is currently advancing an FDA de novo classification application that, if successful, will establish bi-one® as the first cleared technology of its kind in the United States.

Media & Investor Contact

Simmy Pappachen, Chief of Staff

Blue Wellington, LLC

simmy.pappachen@bluewellington.co

2500 Northwinds Parkway, Suite 470 | Alpharetta, GA 30009

About bi-one® / Biodermogenesi®

bi-one® LifeTouchTherapy is the medical device platform delivering Biodermogenesi®, a patented non-invasive technology for stimulating the production of new skin tissue, developed by Expo Italia Srl in Florence, Italy. The technology combines vacuum-assisted electromagnetic fields with low-intensity electrostimulation to stimulate the production of new skin tissue with no downtime or side effects. The platform is CE-marked and has been validated in peer-reviewed clinical studies conducted in collaboration with the Universities of Pisa, Pavia, and Verona across more than 1,000 documented patients. Learn more at www.bi-one.it.

About Blue Wellington, LLC

Blue Wellington is a medical technology accelerator whose mission is to accelerate actionable solutions for transformative medical innovation. Operating as a holding company for direct investments in early-stage healthcare and life science companies, Blue Wellington brings an exceptional multidisciplinary team, a world-class network of subject matter experts, and broad capital markets experience to each of its portfolio companies. Blue Wellington is headquartered in Alpharetta, Georgia. Learn more at www.bluewellington.co.

This press release contains forward-looking statements within the meaning of applicable securities laws, including statements regarding regulatory timelines, commercial launch plans, and market development activities. Actual results may differ materially from those anticipated due to regulatory, clinical, commercial, and other factors. Blue Wellington, LLC undertakes no obligation to update these forward-looking statements. The clinical data referenced herein reflects peer-reviewed published research conducted in international markets. bi-one® / Biodermogenesi® has not been cleared or approved by the U.S. Food and Drug Administration for commercial distribution in the United States.

More News

May 16, 2026

Blue Wellington Appoints Medtech Aesthetics Veteran Robert Fielitz to Management & Advisory Team

A globally recognized commercial leader with more than three decades of international experience scaling the medical aesthetics industry’s most respected ...

April 24, 2026

Blue Wellington Acquires bi-one® to Scale a Differentiated Global Aesthetics Platform

The acquisition unites bi-one®’s patentedLifeTouchTherapy platform— the only clinically validated, non-invasive technology shown to improve stretch marks and scars across ...

March 19, 2026

Blue Wellington Appoints Dan Kiley as Chief Investment Officer of bi-one®

A seasoned investment executive with nearly four decades of asset management and entrepreneurial experience, Kiley brings a disciplined capital stewardship ...

Partner. Collaborate. Accelerate.

Robert Fielitz
– Global commercial operations, international distributor strategy, and market development in medical aesthetics and energy-based devices

Robert Fielitz is a senior executive with over three decades of experience building and scaling international commercial operations for the world’s leading medical aesthetic device companies. He currently serves as SVP & Managing Director of International Distributor Operations at Candela Medical, and previously held senior leadership roles including VP & Managing Director of EMEA Operations and ultimately President & Managing Director of International Operations at Syneron-Candela — with commercial responsibility across plastic surgery, dermatology, and aesthetic medicine markets spanning more than 102 countries across Europe, the Middle East, Africa, and beyond. Earlier in his career he held senior international roles at Palomar Medical Technologies and began in international marketing at Lumenis, a pioneer in laser and light-based medical technology.

Robert’s track record brings firsthand expertise in the full mechanics of taking a medical device technology global: structuring international distributor agreements across diverse regulatory frameworks, building market entry and pricing strategies for novel device categories, and developing the commercial infrastructure to sustain long-term growth. Robert has repeatedly guided go-to-market strategy, regulatory navigation, and the international pricing decisions required to scale medical aesthetic devices at the highest levels of the industry.

Dr. Anne Wetter, MD
– Medical and Aesthetic dermatology, physician education and specialist training, Clinical thought leadership and public speaking

Dr. Anne Wetter is a licensed physician and board-certified dermatologist, and the founder of Diagnostiskt Centrum Hud and Inskinity, where she serves as CEO of Sweden’s largest dermatology practice. She specializes in advanced aesthetic and medical dermatology, including injection therapies, laser treatments, and dermatologic surgical procedures, serving a broad patient base across Sweden.

In addition to her clinical leadership, Dr. Wetter serves as Director of Studies for specialist physician training at Diagnostiskt Centrum Hud and is a respected lecturer nationally and internationally. In 2020, she founded Inskinity Academy to advance physician education and elevate the quality and safety standards of dermatologic and aesthetic treatments. Dr. Wetter is also the founder of the Aesthetic Injection Council, established to promote regulatory standards, improve treatment oversight, and reduce patient complications in Sweden’s rapidly expanding aesthetic injection market. Earlier in her career, she developed Allél Skincare, a personalized skincare line leveraging DNA-based testing to tailor formulations to individual genetic profiles and specific skin needs.

Bill Siren
– Healthcare and Life Sciences corporate strategy, strategy execution, mergers & acquisitions, scaling companies, C-suite leadership

Bill brings more than 35 years of experience as a healthcare executive and currently serves as a Senior Managing Director in Deloitte’s Life Sciences and Health Care practice. He advises C‑suite leaders and private equity firms across the healthcare provider and MedTech sectors, with a focus on strategy, growth, digital transformation, and operational and financial resiliency.
In addition, he has over 20 years of experience in M&A, partnerships, integration planning, post-merger integration, and turnaround management. Bill created StrategyAccelerator, Deloitte’s preeminent strategic transformation and initiative‑management platform. Earlier in his career, he spent nearly a decade in executive roles within both nonprofit and for‑profit hospital systems, including Chief Strategy, Chief Development, Chief Operating, and Chief Executive Officer positions.

Bill currently leads Deloitte’s Nashville Consulting Office (~700 strong) and co‑leads the firm’s Health Care Chief Strategy Officer program. He serves on the board of an international medical device company, is a limited partner in a Nashville‑based venture capital firm and an active investor in healthcare, MedTech, real estate, and golf hospitality ventures.

Connor Seidenschwarz
– Market intelligence and competitive analysis, marketing and growth strategy, product positioning and messaging

Connor Seidenschwarz is a marketing and growth strategy advisor with over eight years of experience advising senior and C-suite executives across global organizations. He specializes in translating complex market intelligence into clear, actionable strategies that inform executive decision-making, product positioning, and enterprise go-to-market initiatives for growth-oriented businesses.

Connor’s work centers on identifying emerging market dynamics, sharpening competitive positioning, and structuring executive-level narratives that support investment decisions, commercialization planning, and strategic expansion. He brings a disciplined, research-driven approach to strategy development, combining analytical rigor with practical execution to drive measurable business outcomes.

Previously, Connor served as a senior researcher at Gartner, where he advised global service and support leaders on strategic transformation, technology adoption, and operational performance. His experience reinforced a product- and customer-centric approach to strategy, with a focus on differentiation, clarity, and scalable execution.

Dan Kiley
– Investment management and portfolio oversight, Entrepreneurship and company building

Dan Kiley Dan Kiley has enjoyed a 38-year career as founder and CEO of Retirement Corporation of America, a nationally recognized investment advisory firm that he sold to Fifth Third Bank in 2017. In May 2022, Retirement Corporation of America was sold back to an investor group which included Dan Kiley and he rejoined the firm in the role of Chief Investment Officer. Managing RCA’s $800,000,000 in client investment assets has always been a passion for Dan and he is excited to be engaged in this role.

As an active entrepreneur, Dan co-founded several other successful businesses:

Money Masters – one of America’s first online investment advisory services. Retirement University which offers classes to retirees on topics such as financial planning, health and nutrition, technology, as well as hobbies and crafts. Diligent Corporation where Diligent Board Books – the flagship software product – is now used by over 25,000 global companies for the secure digital transmission and storage of their confidential corporate information.

He currently serves as a General Partner of Scenic Land Investments which recently developed a premier golf course/hotel/residential community in Rising Fawn, Georgia named McLemore. He is past Chairman of Arria, a global AI NLG technology company.

Amanda Briscoe
– FDA regulatory and international clinical strategy expertise. CMS reimbursement, coverage, and market access advisory. Quality systems (QMS), compliance, and cybersecurity oversight

Amanda Briscoe brings global expertise in regulatory affairs, quality assurance, and reimbursement, integrating regulatory, clinical, and financial strategy to accelerate approvals, optimize pricing, and secure durable market access. Her leadership is anchored in rigorous market analysis, portfolio optimization, and scalable commercialization frameworks that drive long-term shareholder value. A recognized industry leader, she leverages a global network of strategic partners and key opinion leaders to strengthen competitive positioning and sustain commercial success.

Dain Syverson
– International executive search and talent acquisition in medical device, medical products, biotechnology, and medical distribution sectors

Dain Syverson is a Los Angeles native and now based in Atlanta, Dain is the President & Founder of The Syverson Group, LLC (TSG). He serves as the primary search executive engaging with clients in the Diagnostics, Medical Device, Medical Products, Biotechnology, Life Sciences, Pharmaceutical, Dental and Medical Distribution sectors. Dain’s clients include Fortune 500, high growth mid-cap, privately held, private equity group and venture capital-backed firms with focus on Board members; C level; Divisional President and General Management; Vice President and Director Level responsibilities.

Dain’s unique combination of recent business and relevant market experience, key relationships within the industry, ability to assess and attract interest of top executive talent and negotiate mutually acceptable terms & conditions for TSG clients and candidates is unrivaled in the talent acquisition industry.

Prior to founding TSG, Dain served as an Executive Vice President & Partner for over 10 years at a start up search firm where he served as an Officer of the company, led the organization into numerous new verticals, was personally consistently ranked in the Top 1% nationally, built a successful Retained Search offering and developed a reputation in the talent acquisition market for high integrity & authenticity, transparency, tireless work ethic and exceptional performance.

Prior to his talent acquisition start up experience, Dain’s corporate background consisted of over 13 years with Abbott Labs, Diagnostics Division inclusive of executive level responsibilities in General Management, Global & Tactical Marketing, Corporate Accounts, Sales & Sales Management and International Operations. During Dain’s corporate career, he was promoted to increased scopes of responsibility ten (10) times and relocated on seven (7) occasions throughout the U.S. and Europe.

Richard Pines
– Capital Formation,
Strategic Capital Structuring,
Business Development

Richard Pines founded Structured Alpha Solutions LLC in 2019 to help innovative healthcare companies accelerate the growth of their businesses and achieve their financial and operational objectives. To date, Structured Alpha Solutions has been hired by both public and private healthcare companies. Previously, Richard Pines co- founded Athyrium in 2008 and served as a Partner and member of the investment committee, helping to raise ~$3.7B of AUM across three funds in less than a decade. Mr. Pines sourced and identified attractive investment opportunities through his deep network of contacts within the healthcare industry. During his time at Athyrium, Mr. Pines was the sole partner on the following healthcare investments: Paradigm Spine (Acquired), BioFire Diagnostics (Acquired), Verenium (Acquired), Universal Biosensors (technology acquisition), Retrophin, Synarc-Biocore (Acquired), Apollo Endosurgery, Cipher Pharmaceuticals, Medicrea (Acquired), HLS Therapeutics, Recro Pharma and Veloxis (Acquired).

Chris Hughes
– Medical Technology,
FDA Regulations & Compliance

Chris Hughes has been in the medical device industry for 30 years. He founded and is the President & CEO of OsteoRemedies®, LLC. Chris has led this company with a vision to be the premier choice for surgeons by providing simple solutions to complex disorders focused on revision and infection remedies. He has held various leadership roles throughout his career starting with 4 years of active duty as a Captain, in the United States Army. Since 1993, he has been in the medical device industry in sales, marketing, business development, and executive management. Chris held many executive roles at Medtronic Spine & Biologics before his tenure as President of Paradigm Spine, LLC, and then President of CMS, LLC, a medical device distribution entity. Chris earned his Bachelor of Science degree at the University of Tampa and a Master of Business Administration degree from Chaminade University. Chris furthered his Executive Education by attending courses at The Wharton School of Business at the University of Pennsylvania and the Darden School of Business at the University of Virginia. Over his career, Chris has held several appointments as a board member and volunteer, including Co-Chair of the Children’s Brain Tumor Foundation of New York City and Board Chairman of One Family Memphis / Memphis Rox.

Brad Fernald
– Medical Device Expert,
Healthcare Technology

Brad Fernald is a distinguished medical device executive with a passion and proven track record of launching disruptive and innovative startup companies and technologies in the medical field. As the US President of Omniscient Neurotechnology, Brad is currently leading the charge in using AI and machine learning to revolutionize the diagnosis and treatment of neurological and psychiatric diseases by leveraging brain data. Before joining Omniscient Neurotechnology, Brad held a senior executive role at Synaptive Medical, where he oversaw the development of commercial and product strategies for their surgical robotics and imaging businesses. To date, Synaptive has raised over $253M in funding. Prior to Synaptive, Brad spearheaded the development of key clinical applications and commercial strategies of an MRI- guided laser ablation technology for Visualase, a Houston-based startup, which was later acquired by Medtronic for $105M at over 10x equity invested. Brad holds a degree in Mathematics from the University of Florida and a graduate degree in Biomedical Engineering from Florida International University.

Gary Cantrell
– Healthcare Technology,
Engineering, Design &
Manufacturing

Gary Cantrell brings more than 25 years as an information technology executive. Gary served as Global CIO of Jabil, a leading provider of design engineering and manufacturing solutions to numerous industries including healthcare with 260,000 employees in 30 countries. As CIO, he partnered with business leaders to improve operational efficiency, transition to cloud-based solutions and digital transformation. Previously, Gary served as CIO of Textron, a global network of aircraft, defense, industrial and finance businesses providing innovative solutions. Gary led Global IT, risk and supply chain management encompassing $500M annual investment. He has a B.S. and M.B.A. from the University of Dayton has completed Executive education at Wharton, and Advanced Analytics at University of South Florida.

Dr. Jack Bierly, MD
– Aesthetics, Strategic
Investor Relations, Clinician
Relationships and Research

John (Jack) Bierly, MD has a diverse background in both healthcare and real estate development. Dr. Bierly founded both the Southeast Eye Specialist (SEES Group) and Scenic Land Companies. Dr. Bierly has extensive experience in the de-novo start-up of ophthalmic surgery centers as well as medical office buildings.

He has also been a founding partner in Southeast Medical Properties, Surgery Center of Athens, Eye Surgery Center of Chattanooga, and Southeast Eye Surgery Center of Knoxville. He is a general partner and board member in Scenic Land Investment Management as well as Scenic Land Company, and Scenic Land Development. He has been intimately involved in the rebranding of Canyon Ridge Resort to Mclemore Resort, and has helped guide the development of the clubhouse, a new 245 key Hilton Curio Collection Canyon Cloud Hotel (scheduled to open in February 2024) and the building of a new golf course, the Outpost (scheduled summer of 2024). The Course at Mclemore has the distinction of winning the best 18th hole for Golf Digest in 2020 and shares this award with Pebble Beach (1980) and Harbour Town Links (2000). In 2017, he helped lead his company to a recapitalization with a private equity company, Flexpoint Ford.

He is currently the President of Southeast Eye Specialists (SEES), and serves on the SEES Group Board since 2017 as well as Scenic Land Companies Boards. He holds a B.A. from Johns Hopkins University, an M.D. from Weill Cornell Medical College, and an M.B.A. from Emory University.

Simmy Pappachen
– Chief of Staff

Simmy Pappachen is Blue Wellington’s Chief of Staff, and brings a strong entrepreneurial and operational background to the position. Her experience spans business development, media, and wellness platforms, giving her a well-rounded perspective on growth, execution, and organization management.

Simmy founded and managed an international bespoke luxury goods company from the ground up and was eventually featured in the Home & Garden section of the New York Times. In her role as company manager she oversaw operations, partnerships, and brand development amid the early emergence of social media marketing. Simmy has also worked with the Baruch College Public Relations Department in New York City, Psychology Today magazine, and The Therapy Directory, where she developed broad experience across communications, platform growth, and institutional messaging in the health space.

Simmy’s background and experience inform her practical and steady approach as Blue Wellington’s Chief of Staff where she works closely with leadership to clarify priorities, navigate processes, and focus on operational growth objectives.

Reid Maclellan, MD
– President and COO

Dr. Reid Maclellan, M.D. is the Founder and CEO of Cortina Health, Inc, an artificial intelligence company with a mission to restore the care in healthcare and improve quality of life for both patients and physicians. Reid is also an Instructor of Surgery at both Harvard Medical School and Boston Children’s Hospital, where he practices and teaches translational medical research. As a key opinion leader in the fields of healthcare technology, vascular anomalies, and lymphedema, he frequently is invited to lecture both nationally and internationally.

Dr. Maclellan completed a general surgery internship at the University of Tennessee College of Medicine Chattanooga. He then completed plastic surgery clinical and research fellowships at Harvard Medical School and Boston Children’s Hospital. He graduated magna cum laude with a B.S. from the University of Alabama at Birmingham. He received his M.D. from the University of Alabama School of Medicine and a post-doctoral Master in Medical Sciences Degree in translational medical research from Harvard Medical School.

Keith Knutsson
– Founder CEO and
Medtech Innovator

Keith Knutsson is Founder and Chief Executive Officer of Blue Wellington, LLC, a life sciences and medical technology accelerator focused on developing and commercializing proprietary technologies. Keith is a visionary leader, skilled fundraiser, entrepreneur, and operator with over 25 years of experience in operations, financial management, and strategic growth across global markets. Keith has led and advised on complex transactions and consolidation strategies internationally and across industries.

Earlier in his career, Keith played a pivotal role in supporting the valuation and negotiation of the sale of Dollar Rent A Car to the Chrysler Corporation and advised on the development and expansion of the EuroDollar Rent a Car network, which became Europe’s largest privately held car rental company.

In addition to his operational leadership, Keith has served in executive roles within family offices, private equity, and institutional investment platforms across the United States, Europe, and Asia. He has led transactions exceeding $3.2 billion and has been a principal investor and advisor in significant commercial and residential real estate ventures, including Bulgari Hotels and Sodipierre Finance.

Blue Wellington Appoints Dan Kiley as Chief Investment Officer of bi-one®

Blue Wellington Appoints Dan Kiley as Chief Investment Officer of bi-one®

Media & Investor Contact

About bi-one® / Biodermogenesi®

About Blue Wellington, LLC

More News

Blue Wellington Appoints Medtech Aesthetics Veteran Robert Fielitz to Management & Advisory Team

Blue Wellington Acquires bi-one® to Scale a Differentiated Global Aesthetics Platform

Blue Wellington Appoints Dan Kiley as Chief Investment Officer of bi-one®

Reach out to us.

Partner. Collaborate. Accelerate.